Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

TSX:BCT - Post by User

Briacell Therapeutics Corp.

Bullboard Posts

Comment by Pandoraon Mar 24, 2020 10:42pm

242 Views

Post# 30844156

RE:RE:RE:Ipo pricing

Well some of you may have noticed my move into IBIO has not worked out all that well From $1.51 down to $1.11 and this is a Covid-19 play. Can't win for losing as usual. In the meantime the BCT has gone from $19.16 down $10.06 to $9.10.

Not sure what the status is on trials, moving to the U.S. exchange, etc. but it's a very uncertain time.

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions